DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for fg syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFg syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fg syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
mediator complex subunit 12 (MED12) — MED12 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TQ2 · 3.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
FG syndrome is an X-linked condition first described in 1974. A 1985 report of seven males from four families listed mental retardation, congenital hypotonia, severe constipation, structural anal anomalies, relative macrocephaly in some, and a characteristic facial appearance as core features. One of the seven had anal stenosis. Two mothers and one sister showed probable carrier manifestations. The authors stressed that the combination of features is needed to avoid overdiagnosis, because individual signs are non-specific.
A 2005 review of 177 FG syndrome patients from a single clinical genetics research chart found developmental delay in 84%, facial abnormalities in 86%, head abnormalities in 81%, neurological abnormalities in 81%, musculoskeletal or skin abnormalities in 81% and 49% respectively, constipation in 50%, cardiac defects in 41%, genitourinary anomalies in 40%, and radiographic findings in 42%. Corpus callosum thinning or hypoplasia was seen in 18%, absence of the corpus callosum in 10%, and a tethered cord in 2%. The same review noted a possible increased incidence of autoimmune disorders in carrier women, including lupus, scleroderma, autoimmune pericarditis, multiple sclerosis, Crohn disease, and fibromyalgia, as well as a possible predisposition to bipolar disorder and anxiety or panic disorders. No placental abnormalities were detected.
Genetic studies have mapped several loci but no single gene has been confirmed as the cause. A 2007 report described a previously unreported missense mutation in the Filamin A gene (FLNA), P1291L, in a boy with FG syndrome, adding FG syndrome to the list of Filamin A-related disorders. The authors stated that further FLNA studies in other children with FG syndrome would help confirm this association. A 2005 study using comparative genomic hybridization microarray found an inherited duplication at Xq22.3 in a boy with FG syndrome, a region outside the four previously mapped loci (FGS1-4), and proposed this as a new locus, FGS5. The MID2 gene, related to MID1 mutated in Opitz G/BBB syndrome, maps within the duplicated segment and was considered a candidate. The same study noted that FG and Opitz G/BBB syndromes share many manifestations. A 2011 post-mortem report of a nearly 6-year-old boy diagnosed with FG syndrome stated that the phenotype did not suggest involvement of the MED12 gene.
What remains missing is a confirmed genetic mechanism: no single gene has been cloned for any of the five mapped loci, and the association with FLNA has not been replicated in a larger series. The condition is diagnosed clinically, and the overlap with Opitz G/BBB syndrome complicates classification. No systematic trial of any drug for FG syndrome has been reported. The natural history, genotype-phenotype correlations, and the reported autoimmune and psychiatric associations in carriers all require prospective, well-characterised cohorts and funding for basic genetic and clinical research.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2007 · 49 citations
<i>Filamin A</i> mutation is one cause of FG syndrome
AbstractFG syndrome was originally described as a rare syndromic cause of X-linked mental retardation associated with congenital heart disease, anal atresia, inguinal hernia, cryptorchidism, and other anomalies. However, recent reports have highlighted the more common milder presentation which has for cardinal features developmental delay, particularly in speech, neonatal hypotonia, relative macrocephaly, dysmorphic facial features, severe constipation, and few if any congenital malformations. Thus far, five separate loci have been identified on the X chromosome but attempts at finding the responsible gene have not yet been successful. Given that one putative FG locus (FGS2) is situated at Xq28, which is the location of the Filamin A gene (FLNA), and that a Filamin A mutation was reported in a boy with facial dysmorphism and constipation, it was hypothesized that Filamin A mutations could be one cause of FG syndrome. Indeed, a previously unreported FLNA missense mutation (P1291L) was detected in our patient with FG syndrome, thus supporting this hypothesis and indicating that FG syndrome could now be added to the list of Filamin A-related disorders. Filamin A studies in other children with FG syndrome would help to confirm this association.
AbstractThe X-linked FG syndrome is characterised by mental retardation, congenital hypotonia and constipation (which may both be severe), structural anal anomalies and relative macrocephaly in some, and an unusual and characteristic facial appearance. We describe 7 males from 4 families. One had anal stenosis. Two of the mothers and one sister show probable carrier manifestations. The features of the FG syndrome are individually non-specific. We emphasize that the characteristic combination of features is needed to avoid overdiagnosis.
American Journal of Medical Genetics Part A · 2005 · 33 citations · open access
An Xq22.3 duplication detected by comparative genomic hybridization microarray (<i>Array‐CGH</i>) defines a new locus (<i>FGS5</i>) for FG syndrome
AbstractFG syndrome is an X-linked multiple congenital anomalies (MCA) syndrome. It has been mapped to four distinct loci FGS1-4, through linkage analysis (Xq13, Xp22.3, and Xp11.4-p11.3) and based on the breakpoints of an X chromosome inversion (Xq11:Xq28), but so far no gene has been identified. We describe a boy with FG syndrome who has an inherited duplication at band Xq22.3 detected by comparative genomic hybridization microarray (Array-CGH). These duplication maps outside all four loci described so far for FG syndrome, representing therefore a new locus, which we propose to be called FGS5. MID2, a gene closely related to MID1, which is known to be mutated in Opitz G/BBB syndrome, maps within the duplicated segment of our patient. Since FG and Opitz G/BBB syndromes share many manifestations we considered MID2 a candidate gene for FG syndrome. We also discuss the involvement of other potential genes within the duplicated segment and its relationship with clinical symptoms of our patient, as well as the laboratory abnormalities found in his mother, a carrier of the duplication.
Fetal and Pediatric Pathology · 2011 · 0 citations
The FG Syndrome from a Pathological Perspective
AbstractWe report on a case of FG syndrome in an almost 6-year-old boy, diagnosed post-mortem. The description of the intellectual and behavior phenotype provided by the mother, together with the evidence gathered at autopsy, were sufficient to reach a clinical diagnosis. The mother had mild manifestations, including a symptomatic tethered cord, which established her as a carrier of the putative mutation causing the syndrome in the son. The propositus' phenotype did not suggest involvement of the MED12 gene.
Journal of Investigative Medicine · 2005 · 0 citations
338 THE FG SYNDROME: FROM 1974-2004
Abstract<h3></h3> FG syndrome is an X-linked disorder comprising developmental delay, congenital hypotonia, characteristic facial appearance, large head relative to length or height, and other anomalies affecting the genitourinary, gastrointestinal, and musculoskeletal systems. Previous work has demonstrated the range of anomalies seen in FG syndrome, but no single study has presented all of the anomalies in a large series of patients. We retrospectively reviewed 177 FG syndrome patients in our Opitz Clinical Genetics Research charts to identify the relative frequencies of characteristic historical and physical findings. The purpose of this study was to accomplish the following: 1. Attempt to summarize the spectrum of anomalies seen in FG syndrome in patients from the earliest cases in the 19709s to those seen in a clinical genetics practice in 2004. 2. Identify aspects of this presentation that may help elucidate the pathogenetic mechanisms responsible for the disorder. 3. Determine which specific clinical traits are associated with severe forms of the disorder. We identified abnormalities of the head in 81%, of the face in 86%, the musculoskeletal or skin systems in 81% and 49%, respectively, constipation in 50%, neurological abnormalities in 81%, cardiac defects in 41%, genitourinary anomalies in 40%, and developmental delay in 84%. Radiographic findings were seen in 42% of our patients. Corpus callosum thinning or hypoplasia was identified in 18% and absence of corpus callosum was seen in 10%. A tethered cord was clearly diagnosed in 2%. No placental abnormalities were detected in any mother. From our most recent work, it appears that there may be an increased incidence of autoimmune disorders in carrier women including lupus, scleroderma, autoimmune pericarditis, multiple sclerosis, Crohn disease, and “fibromyalgia.” Furthermore, there may be a predisposition to bipolar disorder and anxiety/panic disorders. Based on these findings, we conclude that FG syndrome is seen in a wide range of clinical settings. Severely affected individuals will often benefit from genetic insights into other aspects of their care not commonly seen by primary care physicians. Future work will attempt to determine the relationship between genotype and phenotype in a more rigorous fashion, particularly after the cloning of the four FGS genes mapped so far. Since FGS overlaps extensively with the GBBB syndrome, it is postulated that FGS will also be related to a microtubular-associated protein (MAP) abnormality.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
